Literature DB >> 12767279

Transcriptional inhibition of the human insulin receptor gene by aldosterone.

Consuelo Calle1, Javier Campión, Moisés García-Arencibia, Begoña Maestro, Norma Dávila.   

Abstract

In earlier studies, we reported reduced human insulin receptor (hIR) mRNA levels, insulin binding and insulin responsiveness in U-937 human promonocytic cells treated with aldosterone. The mechanism for this inhibition could be diminished IR gene transcription, since aldosterone did not affect hIR mRNA stability. All the effects were mediated by a downregulation of the mineralocorticoid receptor (MR, NR3C2) expressed at both the RNA and protein levels, suggesting that MR could act as a transcription factor that binds to hormone response elements in the hIR gene promoter. Indeed, MR has been shown to bind glucocorticoid response elements (GREs) in target genes. Given that five GREs have been characterized in the hIR promoter, we decided to test whether these elements could mediate the aldosterone-elicited inhibition of hIR expression detected by us in U-937 cells. In the present report, we demonstrate that aldosterone inhibits the activity of the hIR wild-type promoter by 23%, and causes 23 and 31% reductions in the activity of progressive deletions of this promoter comprised of fragments up to -1473 and -876bp, respectively. This indicates that the -876 to -271bp region of the hIR promoter may be sufficient for this transcriptional inhibition by aldosterone. We also provide evidence for direct MR interaction with some of the GREs of this promoter region, specifically with the cGRE1 and cGRE3, presumably as MR-MR homodimers, and with pGRE as a MR-GR heterodimer. This heterodimer may play the most relevant role and participate in the cross-talk between mineralocorticoids, glucocorticoids and insulin signalling in U-937 cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767279     DOI: 10.1016/s0960-0760(03)00072-4

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

Review 1.  Aldosterone and cardiovascular risk.

Authors:  Bruno Vogt; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

Review 2.  Mineralocorticoid receptor antagonists and the metabolic syndrome.

Authors:  Amir Tirosh; Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 3.  Targeting inflammation in metabolic syndrome.

Authors:  Francine K Welty; Abdulhamied Alfaddagh; Tarec K Elajami
Journal:  Transl Res       Date:  2015-07-03       Impact factor: 7.012

Review 4.  Secondary diabetes mellitus due to primary aldosteronism.

Authors:  Melpomeni Moustaki; Stavroula A Paschou; Eleni C Vakali; Andromachi Vryonidou
Journal:  Endocrine       Date:  2022-08-24       Impact factor: 3.925

5.  Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat.

Authors:  Jayaraman Selvaraj; Sampath Sathish; Chinnaiyan Mayilvanan; Karundevi Balasubramanian
Journal:  Mol Cell Biochem       Date:  2012-09-25       Impact factor: 3.396

6.  Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat.

Authors:  Guido Lastra; Adam Whaley-Connell; Camila Manrique; Javad Habibi; Alex A Gutweiler; Lama Appesh; Melvin R Hayden; Yongzhong Wei; Carlos Ferrario; James R Sowers
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-04-29       Impact factor: 4.310

7.  Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Javad Habibi; Yongzhong Wei; Alex Gutweiler; Jessica Jellison; Charles E Wiedmeyer; Carlos M Ferrario; James R Sowers
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-04

8.  Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population.

Authors:  Yi Chen; Xueyang Chen; Qiang Chen; Chaohui Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-22       Impact factor: 5.555

9.  Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension.

Authors:  E Lucenteforte; C Bosetti; R Talamini; M Montella; A Zucchetto; C Pelucchi; S Franceschi; E Negri; F Levi; C La Vecchia
Journal:  Br J Cancer       Date:  2007-10-02       Impact factor: 7.640

10.  The vitamin D system is deregulated in pancreatic diseases.

Authors:  Doris Hummel; Abhishek Aggarwal; Katalin Borka; Erika Bajna; Enikö Kállay; Henrik Csaba Horváth
Journal:  J Steroid Biochem Mol Biol       Date:  2014-07-30       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.